Medicus Pharma Ltd Stock Performance
| MDCX Stock | USD 3.72 0.59 18.85% |
Medicus Pharma holds a performance score of 9 on a scale of zero to a hundred. The company secures a Beta (Market Risk) of 0.69, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, Medicus Pharma's returns are expected to increase less than the market. However, during the bear market, the loss of holding Medicus Pharma is expected to be smaller as well. Use Medicus Pharma value at risk, and the relationship between the jensen alpha and skewness , to analyze future returns on Medicus Pharma.
Risk-Adjusted Performance
OK
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Medicus Pharma Ltd are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak fundamental indicators, Medicus Pharma showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 14.46 | Five Day Return 11.04 | Year To Date Return 48.21 | Ten Year Return 40.38 | All Time Return 40.38 |
1 | Insider Trading | 12/31/2024 |
2 | Medicus Pharma Ltd. Enters into Standby Equity Purchase Agreement and Announces Intention to Voluntarily Delist from the TSX Venture Exchange | 02/11/2025 |
3 | Medicus Pharma Provides Update on SKNJCT-003 Phase 2 Clinical Study for the Treatment of Nodular Basal Cell Carcinoma | 02/14/2025 |
4 | Medicus Pharma Ltd Announces Submission of Phase 2 Clinical Design to United Arab Emirates Department of Health to Non-Invasively Treat Basal Cell Carcinoma of ... | 02/27/2025 |
5 | Medicus Pharma Ltd Announces Positively Trending Interim Analysis for SKNJCT-003 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin | 03/06/2025 |
6 | 3 US Healthcare Stocks That Might Be Undervalued 2025 - Value the Markets | 03/21/2025 |
7 | Medicus Pharma Ltd. SEC 10-K Report - TradingView | 03/28/2025 |
| Begin Period Cash Flow | 267.7 K | |
| End Period Cash Flow | 1.7 M |
Medicus |
Medicus Pharma Relative Risk vs. Return Landscape
If you would invest 251.00 in Medicus Pharma Ltd on January 1, 2025 and sell it today you would earn a total of 121.00 from holding Medicus Pharma Ltd or generate 48.21% return on investment over 90 days. Medicus Pharma Ltd is currently generating 1.0449% in daily expected returns and assumes 8.8666% risk (volatility on return distribution) over the 90 days horizon. In different words, 79% of otc bb equitys are less volatile than Medicus, and 79% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Medicus Pharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Medicus Pharma's investment risk. Standard deviation is the most common way to measure market volatility of otc bb equitys, such as Medicus Pharma Ltd, and traders can use it to determine the average amount a Medicus Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1178
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | MDCX | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 8.87 actual daily | 79 79% of assets are less volatile |
Expected Return
| 1.04 actual daily | 20 80% of assets have higher returns |
Risk-Adjusted Return
| 0.12 actual daily | 9 91% of assets perform better |
Based on monthly moving average Medicus Pharma is performing at about 9% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Medicus Pharma by adding it to a well-diversified portfolio.
Medicus Pharma Fundamentals Growth
Medicus OTC BB Equity prices reflect investors' perceptions of the future prospects and financial health of Medicus Pharma, and Medicus Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Medicus OTC BB Equity performance.
| Current Valuation | 44.65 M | ||||
| Price To Earning | (0.21) X | ||||
| Price To Book | 14.21 X | ||||
| EBITDA | (323.24 K) | ||||
| Net Income | (6.78 M) | ||||
| Cash And Equivalents | 1.22 K | ||||
| Total Debt | 1.09 M | ||||
| Book Value Per Share | (0.13) X | ||||
| Cash Flow From Operations | (4.16 M) | ||||
| Total Asset | 1.89 M | ||||
| Retained Earnings | (19.18 M) | ||||
About Medicus Pharma Performance
Evaluating Medicus Pharma's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Medicus Pharma has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Medicus Pharma has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Medicus Pharma is traded as part of a regulated electronic trading service offered by the NASD. Medicus Pharma is required by the National Association of Securities Dealers to file current financial statements with the SEC or a bankinginsurance regulator. The quote is listed on Over-The-Counter Bulletin Board , and the company does not need to meet listing requirements such as those found on the Nasdaq, NYSE, or AMEX exchanges.Things to note about Medicus Pharma performance evaluation
Checking the ongoing alerts about Medicus Pharma for important developments is a great way to find new opportunities for your next move. OTC BB Equity alerts and notifications screener for Medicus Pharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Medicus Pharma is way too risky over 90 days horizon | |
| Medicus Pharma appears to be risky and price may revert if volatility continues | |
| Medicus Pharma Ltd currently holds 1.09 M in liabilities. Medicus Pharma has a current ratio of 0.52, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Medicus Pharma's use of debt, we should always consider it together with its cash and equity. | |
| Net Loss for the year was (6.78 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Medicus Pharma Ltd currently holds about 1.22 K in cash with (4.16 M) of positive cash flow from operations. | |
| Latest headline from news.google.com: Medicus Pharma Ltd. SEC 10-K Report - TradingView |
- Analyzing Medicus Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Medicus Pharma's stock is overvalued or undervalued compared to its peers.
- Examining Medicus Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Medicus Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Medicus Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Medicus Pharma's otc bb equity. These opinions can provide insight into Medicus Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Medicus OTC BB Equity Analysis
When running Medicus Pharma's price analysis, check to measure Medicus Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medicus Pharma is operating at the current time. Most of Medicus Pharma's value examination focuses on studying past and present price action to predict the probability of Medicus Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medicus Pharma's price. Additionally, you may evaluate how the addition of Medicus Pharma to your portfolios can decrease your overall portfolio volatility.